Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

Browse by...

Deposit

Highlights

More informations

Title		Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
Authors		Strand, Vibeke Michalska, Margaret Birchwood, Christine Pei, Jinglan Tuckwell, Katie Finch, Rebecca Gabay, Cem Kavanaugh, Arthur Jones, Graeme show all authors [1 - 9]
Published in		RMD open. 2017, vol. 3, no. 2, e000496
Abstract		Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA.
Identifiers		DOI: 10.1136/rmdopen-2017-000496 PMID: 28955499
Full text		Article (Published version) (3 MB) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Mécanisme de l'inflammation articulaire (44)
Citation (ISO format)		STRAND, Vibeke et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. In: RMD Open, 2017, vol. 3, n° 2, p. e000496. doi: 10.1136/rmdopen-2017-000496 https://archive-ouverte.unige.ch/unige:110661